A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

Cancer

Volumn 92, Issue 5, 2001, Pages 1265-1271

  Casey Cunningham, C ^a,b   Holmlund, John T ^c   Geary, Richard S ^c   Jesse Kwoh, T ^c   Dorr, Andrew ^c   Johnston, Joseph F ^c   Monia, Brett ^c   Nemunaitis, John ^a,b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; Pharmacokinetics; Pharmacology; Therapeutic use; Toxicity

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ISIS 2503;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; LYMPHOCYTE; ONCOGENE H RAS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035447768     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010901)92:5<1265::AID-CNCR1447>3.0.CO;2-5     Document Type: Article

References (21)